Primary vitreoretinal lymphoma (PVRL) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Primary vitreoretinal lymphoma (PVRL)

Primary vitreoretinal lymphoma (PVRL) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Primary vitreoretinal lymphoma (PVRL) is a rare B-cell intraocular malignancy, commonly considered as a subset of primary central nervous system (CNS) lymphoma. Brain dissemination occurs in 60–90% of patients and it is the cause of the high mortality and morbidity of the disease. PVRL involves the vitreous, the retina, and the retinal pigment epithelium (RPE). According to literature around 15–20% of patients with primary central nervous system lymphoma (PCNSL) will develop PVRL later. The majority of PVRL is of B-cell origin. However, T-cell lymphomas and T-cell rich lymphomas can also develop within the eye.

Epidemiology-

PVRL, a rare intraocular malignancy, is a subset of PCNSL It is a rare disease, according to literature PVRL has an approximate incidence in ~20% patients with PCNSL and 0.03 to 0.1 cases per 100,000 people per year in the US. PVRL usually affects the adults in the fifth–sixth decades of life.

Competitive landscape of Primary vitreoretinal lymphoma (PVRL) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Primary vitreoretinal lymphoma (PVRL) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Primary vitreoretinal lymphoma (PVRL) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Primary vitreoretinal lymphoma (PVRL) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 ADX-2191 Aldeyra Therapeutics, Inc. Phase 3